肝细胞癌的流行病学与监测:新趋势
肝细胞癌负担在东亚和非洲最高,但美国和欧洲发病与死亡率快速上升。随着乙肝疫苗接种和丙肝治疗全球推进,病因正从病毒性肝炎为主转向非酒精性脂肪性肝炎比例增加。每6个月超声(联合或不联合甲胎蛋白)监测与早期检出和总生存改善相关,但实施受限导致临床中高比例病例晚期才被发现。
要点
- 全球HCC负担东亚和非洲最高,美欧发病与死亡率快速上升。
- 病因构成转变:病毒性肝炎占比下降,NASH相关比例增加。
- 每6个月超声监测(联合或不联合AFP)与早期检出和总生存改善相关。
核心结论
- HCC流行病学正从病毒性肝炎主导转向NASH相关比例增加,监测实施不足导致晚期检出比例高。
研究设计与样本
- 综述,总结当前HCC监测现状并指出未来研究方向。
主要发现
- HCC负担在东亚和非洲最高,但美国和欧洲发病与死亡率快速上升。
- 全球乙肝疫苗接种和丙肝治疗推进使病毒性肝炎相关HCC比例下降,NASH相关比例增加。
- 每6个月超声(联合或不联合AFP)监测与早期检出改善和总生存改善相关。
- 临床实践中监测实施受限导致高比例HCC在晚期才被检出。
关键数值与推荐
- 监测方案为每6个月超声,可联合或不联合甲胎蛋白。
临床怎么用
- 对HCC高危人群应每6个月进行超声监测,可联合或不联合AFP,以提高早期检出。
- 需关注NASH相关HCC比例上升,相应风险人群应纳入监测。
局限性
- 综述未提供具体风险分层工具、监测敏感度和特异度数值。
- 未报告改善监测利用率的干预措施具体效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although its incidence and mortality are rapidly rising in the United States and Europe. With the implementation of hepatitis B vaccination and hepatitis C treatment programmes worldwide, the epidemiology of HCC is shifting away from a disease predominated by viral hepatitis - an increasing proportion of cases are now attributable to non-alcoholic steatohepatitis. Surveillance using ultrasound, with or without alpha-fetoprotein, every 6 months has been associated with improved early detection and improved overall survival; however, limitations in implementation lead to a high proportion of HCC being detected at late stages in clinical practice. Herein, we review the current state of HCC surveillance and highlight areas for future research, including improved risk stratification of at-risk patients, surveillance tools with higher sensitivity and specificity for early HCC, and interventions to increase surveillance utilisation.
引用
- Singal AG, Lampertico P, Nahon P, et al. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020. PMID: 31954490. doi:10.1016/j.jhep.2019.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。